DNA nanoparticles are safe and nontoxic in non-human primate eyes
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: DNA nanoparticles (NPs) comprising polylysine conjugated to polyethylene glycol efficiently target murine photoreceptors and the retinal pigment epithelium (RPE) and lead to long-term phenotypic improvement in models of retinal degeneration. Advancing this technology requires testing in a large animal model, particularly with regard to safety. So, herein we evaluate NPs in non-human primates (baboon). METHODS AND RESULTS: NPs with plasmids carrying GFP and a ubiquitous, RPE-specific, or photoreceptor-specific promoter were delivered by either subretinal or intravitreal injection. We detected GFP message and protein in the retina/RPE from eyes dosed with NPs carrying ubiquitously expressed and RPE-specific vectors, and GFP message in eyes injected with NPs carrying photoreceptor-specific vectors. Importantly, we observed NP DNA in the retina/RPE following intravitreal injection, indicating the inner limiting membrane does not prevent NP diffusion into the outer retina. We did not observe any adverse events in any baboon, and there were no NP-associated changes in retinal function. Furthermore, no systemic or local inflammatory reaction to the vectors/injections was observed, and no NP DNA was found outside the eye. CONCLUSION: Taken together with the well-established rodent safety and efficacy data, these findings suggest that DNA NPs may be a safe and potentially clinically viable nonviral ocular therapy platform for retinal diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“23 Current retina/RPE-targeted gene therapies are being delivered subretinally; 24,25 however, this procedure is invasive, and long-term sequelae as a result of the injection procedure are thought to impair the efficacy of the treatment.”
The Major Cell Populations of the Mouse Retina
Jeon, C.-J., Strettoi, E., & Masland, R. H. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-21-08936.1998 · Cited by 1,429
Phagocytosis of Retinal Rod and Cone Photoreceptors
Kevany, B. M., & Palczewski, K. (2010) · Physiology · doi:10.1152/physiol.00038.2009 · Cited by 426 · cited 1×
“…phagocytic nature of that tissue which easily takes up both endogenous material such as photoreceptor photoreceptor outer segments as well as exogenous material delivered to the subretinal space, 29,30 and indeed, we have found that the RPE preferentially takes up NP DNA compared to photoreceptors.”
Inner limiting membrane barriers to aav-mediated retinal transduction from the vitreous
Dalkara, D., Kolstad, K. D., Caporale, N., Visel, M., Klimczak, R. R., Schaffer, D. V., & Flannery, J. G. (2009) · Molecular Therapy · doi:10.1038/mt.2009.181 · Cited by 357
Efficient Non-Viral Ocular Gene Transfer with Compacted DNA Nanoparticles
Farjo, R., Skaggs, J., Quiambao, A. B., Cooper, M. J., & Naash, M. I. (2006) · PLoS ONE · doi:10.1371/journal.pone.0000038 · Cited by 208 · cited 2×
“Previously, we had observed gene expression in the cornea and lens after delivery of NPs in the murine eye; 4 however, neither intravitreal nor subretinal injection led to detectable GFP message in the baboon anterior segment tissues (Figure 1A, left).”
Self-citationKim, H., Robinson, S. B., & Csaky, K. G. (2009) · Pharmaceutical Research · doi:10.1007/s11095-008-9745-6 · Cited by 174 · cited 6×
“…even if it is not efficiently taken up/expressed by photoreceptors, a phenomenon that has been seen previously with various other types of NPs. 26,27 Given this observation, and the importance of intravitreal delivery, our future studies will likely focus on optimizing this approach along…”
InfluentialPersistent transgene product in retina, optic nerve and brain after intraocular injection of rAAV
Dudus, L., Anand, V., Acland, G. M., Chen, S.-J., Wilson, J. M., Fisher, K. J., Maguire, A. M., & Bennett, J. (1999) · Vision Research · doi:10.1016/s0042-6989(98)00308-3 · Cited by 160
DNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice
Han, Z., Conley, S. M., Makkia, R. S., Cooper, M. J., & Naash, M. I. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64833 · Cited by 150
Self-citationFink, T. L., Klepcyk, P. J., Oette, S. M., Gedeon, C. R., Hyatt, S. L., Kowalczyk, T. H., Moen, R. C., & Cooper, M. J. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302761 · Cited by 139 · cited 1×
“16 These results confirm that the CK30PEG NP technology has advanced sufficiently to have the potential to be a successful addition to the available repertoire of clinical ocular gene delivery tools.”
Self-citationCai, X., Nash, Z., Conley, S. M., Fliesler, S. J., Cooper, M. J., & Naash, M. I. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005290 · Cited by 109 · cited 2×
“2,3 We have shown that they efficiently transfect both photoreceptors 3,4 and the RPE, 2,4,5 and can improve the disease phenotype in the rds + / − and rhodopsin-knockout models of retinitis pigmentosa, 3,6–8 the Abca4 − / − model of Stargardt’s dystrophy, 9 and the Rpe65 − / − model of Leber’s…”
Self-citation
Cited by
Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain
Pardridge, W. M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00373 · Cited by 405
“Therefore, treatment of the eye required a sub-retinal injection of the polyplex (Kelley et al., 2018).”
BackgroundLipid nanoparticles for delivery of messenger RNA to the back of the eye
Patel, S., Ryals, R. C., Weller, K. K., Pennesi, M. E., & Sahay, G. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.04.015 · Cited by 260
Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives
Bordet, T., & Behar-Cohen, F. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.038 · Cited by 120
The future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery
Ross, M., & Ofri, R. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.306063 · Cited by 67
“Kelley et al. (2018) showed that the DNA NPs were well tolerated in baboon eyes following IVT injection, and that IVT injected NPs were able to drive Green Fluorescent Protein gene expression in RPE and photoreceptor cells, indicating the ILM did not prevent NP diffusion to the outer retina.”
Background
Metadata
- Authors
- Kelley, R. A., Conley, S. M., Makkia, R., Watson, J. N., Han, Z., Cooper, M. J., & Naash, M. I.
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2018-03
- Volume
- Volume 13
- Pages
- 1361-1379
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- OpenAlex
- W2791638265
- Cited by
- 36
- References
- 13
- FWCI
- 1.41
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: DNA nanoparticles are safe and nontoxic in non-human primate eyes. https://app.cochat.ai/papers/10.2147/ijn.s157000
- The paper
- Kelley, R. A., Conley, S. M., Makkia, R., Watson, J. N., Han, Z., Cooper, M. J., & Naash, M. I. (2018). DNA nanoparticles are safe and nontoxic in non-human primate eyes. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s157000
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.